

## Product Information

## CellLytic™ M

Cell Lysis Reagent, suitable for mammalian cell lysis and protein solubilization

**C2978**

### Product Description

Extraction of cell proteins requires efficient cell lysis and protein solubilization, while avoiding protein degradation and/or reagent interference with protein immunoreactivity and biological activity.

The CellLytic™ M mammalian cell lysis/extraction reagent enables efficient and rapid cell lysis, and solubilization of proteins for both suspension and adherent cells such that adherent cells do not require scraping from the culture dish.

CellLytic™ M-extracted proteins can be used for reporter gene assays ( $\beta$ -gal, alkaline phosphatase, and CAT), immunoassays (Western blots, ELISA, and immunoprecipitation), kinase assays (PKC and tyrosine kinase) and phosphatase assays (general and tyrosine phosphatases). CellLytic™ M is compatible with Coomassie® Blue and silver staining of gels. Protein lysates can also be used for DNA-protein interaction assays (gel-shift assays).

CellLytic™ M contains a low percentage of a mild detergent for minimal interference with protein interactions and biological activity. The detergent can be dialyzed out as needed. The product is supplied in a bicine buffer which is suitable for evaluation of biological activity.

CellLytic™ M reagent efficiency for protein extraction has been tested on, but not limited to, HeLa, CHO, COS, HL-60, Jurkat, A431, PC-12, and Bovine Aorta Endothelial Cells (BAEC).

For some applications, lysis at 4 °C and/or the addition of specific components might be advantageous. Such components include protease or phosphatase inhibitor cocktails, reducing agents, chelators, or salts (which may provide better results in immunoassays and better extraction of nuclear proteins).

Several theses<sup>1-3</sup> and dissertations<sup>4-22</sup> have cited use of product C2978 in their research protocols.

### Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

### Reagent

CellLytic™ M is supplied ready-to-use. Sufficient reagent for the extraction of cells from 250 plates (100 mm diameter) is provided.

### Reagents and Equipment Required but Not Provided

(Cat. Nos. are given where available)

- Protease Inhibitor Cocktail suitable for mammalian cell and tissue extracts, such as Cat. Nos. P8340, PIC0002, or I3786
- Test tubes
- Shaker
- Microcentrifuge
- Dulbecco's phosphate-buffered saline (DPBS), Cat. No. D8537

### Storage/Stability

Store at room temperature. The product may appear cloudy after extended period of storage. Product performance is unaffected. The product may be used as is, without further filtration or clarification.

### Procedure

#### General Notes

- The volume of CellLytic™ M to be added to the cells varies according to cell size and protein concentration required.
- In general, 125  $\mu$ L of CellLytic™ M is recommended for  $10^6$ - $10^7$  cells.

- For adherent cells, the plate size will dictate the amount of reagent covering the plate surface. Suggested working volumes are:
  - 500-1000  $\mu$ L for a 100 mm plate
  - 200-400  $\mu$ L for a 35 mm plate
- Protease Inhibitor Cocktail may be added to the CelLytic™ M reagent.

## General Protocol

1. Wash cells and treat with CelLytic™ M.
  - 1.1. For adherent cells:
    - 1.1.1. Remove the growth medium from the cells to be assayed.
    - 1.1.2. Rinse the cells once with DPBS, being careful not to dislodge any of the cells.
    - 1.1.3. Discard DPBS.
    - 1.1.4. Add appropriate volume of CelLytic™ M reagent.
  - 1.2. For cells in suspension:
    - 1.2.1. Collect cells in an appropriate centrifuge tube.
    - 1.2.2. Centrifuge for 5 minutes at  $450 \times g$ .
    - 1.2.3. Decant and discard the supernatant. Wash the cells once with DPBS.
    - 1.2.4. Centrifuge for 5 minutes at  $450 \times g$ .
    - 1.2.5. Decant and discard supernatant.
    - 1.2.6. Resuspend the cell pellet in the recommended volume of CelLytic™ M reagent.
2. Incubate the cells for 15 minutes on a shaker.
3. Collect lysed cells.
  - 3.1. For adherent cells: remove cells from plates. (Cell scraping might increase total protein yield.)
  - 3.2. For cells in suspension: go to Step 4.
4. Centrifuge the lysed cells for 15 minutes at  $12,000-20,000 \times g$  to pellet the cellular debris.
5. Remove the protein-containing supernatant to a chilled test tube.

**Note:** Lysate preservation requires low temperatures. Therefore, for long-term storage, it is recommended to store lysate at  $-70\text{ }^{\circ}\text{C}$ .

## References

1. Bock, Timothy, Jr., "Homology modeling of the *Squalus acanthias ahr1* to locate structural determinants of function in an atypical receptor". Rhode Island College, M.S. thesis, p. 17 (2019).
2. Kim, Hyun Woo Albert, "Development and Characterization of a Controlled Expression System for Osteogenic Genes". University of Toronto, M.Sc. thesis, p. 29 (2011).
3. Mendenhall, Eric Thomas, "An Investigation of the Effect of  $\text{Mn}^{2+}$  on the FTH1 IRE-IRP Complex". Marshall University, M.S. thesis, p. 19 (2015).
4. Koukuntla, Ramesh, "Suppressor tRNA mediated gene therapy". Iowa State University, Ph.D. dissertation, p. 45 (2009).
5. Turner, Sharon Louise, "Investigation of ADAM17 and ADAMTS-1, -4 and -5 in Liver Carcinoma". Sheffield Hallam University, Ph.D. dissertation, p. 52 (2009).
6. Brown, Matthew Ralph Laven, "The expression of toll-like receptors-2 and -4 by human crypt intestinal epithelial cells, intestinal myofibroblasts and putative intestinal stem cells in inflammatory bowel disease". University of Nottingham, Ph.D. dissertation, p. 197 (2012).
7. Masurekar, Ashish Narayan, "Biological determinants of therapeutic response to L-asparaginase in children with acute lymphoblastic leukaemia". University of Manchester, Ph.D. dissertation, pp. 74, 216 (2012).
8. Ogbe, Ane Theodora, "Early Growth Response genes 2 and 3 play a role in chronic inflammation pathology and are essential for the differentiation of T follicular helper cells". Brunel University, Ph.D. dissertation, p. 79 (2015).
9. Órfi, Zoltán, "Targets and Off-Targets of Kinase Inhibitors in Diabetes". Technischen Universität München, Dr. rer. nat. dissertation, p. 28 (2015).
10. Al-Rugaie, Osamah, "Presence and Role of *Acanthamoeba* in Wound Infections". University of Essex, Ph D. dissertation, p. 220 (2016).
11. Francica, Brian J., "Releasing the brakes: strategies to remodel the tumor environment, increase immune infiltrate, and induce tumor cell death". Johns Hopkins University, Ph.D. dissertation, pp. 14, 53, 64, 75 (2016).

12. Massudi, Hassina, "Modulation of SIRT1 as an anti-ageing target". University of New South Wales, Ph D. dissertation, p. 75 (2016).
13. Muzurengi, Sharon, "Improving the management of Parkinson's Disease: the experience of hospitalisation and a novel MRI-based diagnostic tool". University of Birmingham, Ph D. dissertation, p. 203 (2016).
14. Chalari, Eleanna, "The effect of high-intensity intermittent exercise on biomarkers of oxidative stress". University of Hull, Ph.D. dissertation, p. 273 (2017).
15. Giri, Subhajit, "Molecular basis of pathogenesis of dystonia among Indian patients". University of Calcutta, Ph.D. dissertation, p. 126 (2017).
16. Liu, Yang-Lin, "Genomic Studies in Non-Alcoholic Fatty Liver Disease". Newcastle University, Ph.D. dissertation, p. 69 (2017).
17. Wobst, Jana, "Variants in *GUCY1A3* influencing coronary artery disease". Technischen Universität München, Dr. rer. nat. dissertation, p. 16 (2017).
18. Zhang, Zhuo, "Mechanistic PK/PD Modeling of Btk Inhibitors and the Development of PET Tracers for Bacterial Infection Diagnosis". Stony Brook University, Ph.D. dissertation, p. 27 (2017).
19. Moreno, Ann Marie, "New Insights into the Assembly Mechanism of an RNA Polymerase III-Specific Transcription Complex on a *Drosophila* U6 snRNA Gene Promoter". San Diego State University and University of California San Diego, Ph.D. dissertation, p. 22 (2018).
20. Norster, Faith, "Investigating the roles of HMGB1 and its receptor, RAGE, in chronic lymphocytic leukaemia". Queen Mary University of London, Ph.D. dissertation, p. 252 (2018).
21. Nguyen, Ha Phuong, "Synthesis of Chemical Tools for Targeted Epigenetic Modifications". University College London, Ph.D. dissertation, p. 185 (2019).
22. Allard, Julien, "Mise en évidence de l'implication de différents mécanismes dans la survenue de la stéatose hépatique d'origine médicamenteuse en absence de dysfonction mitochondriale sévère" ("Highlighting the involvement of different mechanisms in the occurrence of drug-induced hepatic steatosis in the absence of severe mitochondrial dysfunction"). Université de Rennes, Ph.D. dissertation, p. 135 (2020).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

## Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.  
C2978bul Rev 03/22 BD,CMH,GCY,MAM

